Catalin Bobirca/LinkedIn
Jun 16, 2026, 14:36
Catalin Bobirca: EHA 2026 Showcases the Future of Hemoglobinopathies Care
Catalin Bobirca, Director of Global Medical Affairs Hemoglobinopathies at Novo Nordisk, shared a post on LinkedIn:
“Back from EHA 2026 and feeling incredibly inspired!
The updates in hemoglobinopathies research highlight just how far we’ve come—and where the future of medicine is heading.
Beyond the data, the highlight of my week was connecting (and reconnecting) with so many dedicated physicians and peers.
Thank you for the insightful discussions and your shared commitment to transforming patient lives.
Let’s stay connected!
One special thanks to the team that made all this possible!”
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering